Low-grade prostate cancer: Secondary treatment rates slightly higher with delayed surgery

Key clinical point: Men with low-grade prostate cancer undergoing delayed radical prostatectomy (RP) after an initial period of active surveillance show a small increase in the use of secondary treatments, despite an increase in adverse pathology vs those undergoing immediate RP.

Major finding: The incidence of adverse pathology was higher with delayed vs immediate RP (49% vs 36%; P < .0001). Estimated 24‐month secondary treatment‐free probabilities in patients who received delayed and immediate RP were 93% and 96%, respectively (P = .0023).

Study details: A retrospective study of 1,878 patients with grade group 1 prostate cancer who underwent RP between April 2012 and July 2018.

Disclosures: This study is supported by the Blue Cross Blue Shield of Michigan Foundation. Some authors reported salary support. No other competing interests were disclosed.

Source: Arcot R et al. Prostate. 2021 Dec 2. doi: 10.1002/pros.24277.

Key clinical point: Men with low-grade prostate cancer undergoing delayed radical prostatectomy (RP) after an initial period of active surveillance show a small increase in the use of secondary treatments, despite an increase in adverse pathology vs those undergoing immediate RP.

Major finding: The incidence of adverse pathology was higher with delayed vs immediate RP (49% vs 36%; P < .0001). Estimated 24‐month secondary treatment‐free probabilities in patients who received delayed and immediate RP were 93% and 96%, respectively (P = .0023).

Study details: A retrospective study of 1,878 patients with grade group 1 prostate cancer who underwent RP between April 2012 and July 2018.

Disclosures: This study is supported by the Blue Cross Blue Shield of Michigan Foundation. Some authors reported salary support. No other competing interests were disclosed.

Source: Arcot R et al. Prostate. 2021 Dec 2. doi: 10.1002/pros.24277.

Key clinical point: Men with low-grade prostate cancer undergoing delayed radical prostatectomy (RP) after an initial period of active surveillance show a small increase in the use of secondary treatments, despite an increase in adverse pathology vs those undergoing immediate RP.

Major finding: The incidence of adverse pathology was higher with delayed vs immediate RP (49% vs 36%; P < .0001). Estimated 24‐month secondary treatment‐free probabilities in patients who received delayed and immediate RP were 93% and 96%, respectively (P = .0023).

Study details: A retrospective study of 1,878 patients with grade group 1 prostate cancer who underwent RP between April 2012 and July 2018.

Disclosures: This study is supported by the Blue Cross Blue Shield of Michigan Foundation. Some authors reported salary support. No other competing interests were disclosed.

Source: Arcot R et al. Prostate. 2021 Dec 2. doi: 10.1002/pros.24277.